在102个低收入和中等收入国家5岁及以下儿童中接种志贺菌疫苗的潜在影响与成本效果:一项模型研究
该模型研究估计2025至2044年102个低收入和中等收入国家5岁及以下儿童的志贺菌疾病负担及疫苗接种影响,涵盖与志贺菌相关的中重度腹泻和较轻腹泻所致发育迟缓。总体平均ICER为每避免一个伤残调整生命年849美元,在世卫组织非洲区域和低收入国家最具成本效果。
要点
- 总体平均ICER为每避免一个伤残调整生命年849美元,非洲区域和低收入国家最具成本效果。
核心结论
- 模型提示志贺菌疫苗接种具有成本效果,在特定国家和区域影响显著,其他区域在纳入发育迟缓和较轻腹泻负担后可能获益。
研究设计与样本
- 模拟模型估计2025至2044年102个低收入至中等收入国家5岁及以下儿童的志贺菌疾病负担和疫苗接种影响,模型纳入与志贺菌相关中重度腹泻和较轻腹泻相关的发育迟缓,并评估疫苗接种对健康和经济结局的影响。
主要发现
- 总体平均ICER为每避免一个伤残调整生命年849美元(95%不确定性区间423至1575;中位数790美元[四分位距635至1005])。
- 疫苗接种在世卫组织非洲区域和低收入国家最具成本效果。
- 纳入志贺菌相关较轻腹泻负担后,这些群体的平均ICER改善47%至48%,其他区域ICER也大幅改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccine impact and cost-effectiveness models have mostly focused on acute burden. Shigella-attributable moderate-to-severe diarrhoea has been shown to be associated with childhood linear growth faltering. Evidence also links less severe diarrhoea to linear growth faltering. As Shigella vaccines are in late stages of clinical development, we aimed to estimate the potential impact and cost-effectiveness of vaccination against Shigella burden that includes stunting and the acute burden attributable to less severe diarrhoea and moderate-to-severe diarrhoea. METHODS: We used a simulation model to estimate Shigella burden and potential vaccination in children aged 5 years or younger from 102 low-income to middle-income countries from 2025 to 2044. Our model included stunting associated with Shigella-related moderate-to-severe diarrhoea and less severe diarrhoea and we explored vaccination impact on health and economic outcomes. FINDINGS: We estimate 109 million (95% uncertainty interval [UI] 39-204) Shigella-attributable stunting cases and 1·4 million (0·8-2·1) deaths in unvaccinated children over 20 years. We project that Shigella vaccination could avert 43 million (13-92) stunting cases and 590 000 (297 000-983 000) deaths over 20 years. The overall mean incremental cost-effectiveness ratio (ICER) was US$849 (95% uncertainty interval 423-1575; median $790 [IQR 635-1005]) per disability-adjusted life-year averted. Vaccination was most cost-effective in the WHO African region and in low-income countries. Including the burden of Shigella-related less severe diarrhoea improved mean ICERs by 47-48% for these groups and substantially improved ICERs for other regions. INTERPRETATION: Our model suggests that Shigella vaccination would be a cost-effective intervention, with a substantial impact in specific countries and regions. Other regions could potentially benefit upon the inclusion of the burden of Shigella-related stunting and less severe diarrhoea in the analysis. FUNDING: Bill & Melinda Gates Foundation and Wellcome Trust.
引用
- Anderson JD, Bagamian KH, Pecenka CJ, et al. Potential impact and cost-effectiveness of Shigella vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: a modelling study. Lancet Glob Health. 2023. PMID: 37202023. doi:10.1016/S2214-109X(23)00192-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。